Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Early Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Phase 1
2 (100.0%)Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
Early Phase 1
Completed
- Conditions
- Pancreatic Adenocarcinoma Locally AdvancedPancreatic Adenocarcinoma MetastaticPancreatic Adenocarcinoma Resectable
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Jean-Luc Van Laethem
- Target Recruit Count
- 23
- Registration Number
- NCT01715142
- Locations
- 🇧🇪
Antwerp University Hospital (UZA), Edegem, Antwerpen, Belgium
🇧🇪Erasme University Hospital (ULB), Brussels, Belgium
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
Early Phase 1
- Conditions
- Pancreatic Adenocarcinoma Resectable
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Jean-Luc Van Laethem
- Target Recruit Count
- 21
- Registration Number
- NCT01713218
- Locations
- 🇧🇪
Antwerp University Hospital (UZA), Edegem, Antwerpen, Belgium
🇧🇪Erasme University Hospital (ULB), Brussels, Belgium
News
No news found